Back to discover
Disease
Preleukemia
Active therapeutic pipelineEmerging research
1
Publications
6
Clinical trials
2009
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: Low
Key developments
- 3 clinical trials with recent milestones (1 completed or reporting results).
Major developments
Major trial resultsHigh impact
Results posted2026-06-04
Major clinical milestoneImportant
Primary completion2026-06-01
Clinical MilestonesViewHide
Results posted
Recently completed
- 2026-06-01A Phase 1/1b Open-Label, Dose Escalation, First-in- Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-leukemic Activity of the Orally Available CDC-Like Kinase (CLK) Inhibitor, BH-30236, in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML) or Higher-Risk Myelodysplastic Syndrome (HR-MDS)Primary completion
- 2026-02-01STOP-LEUKEMIA: Repurposing Metformin As a Leukemia-preventive Drug in CCUS and LR-MDSPrimary completion
Activity timeline3
- 2026-06-04ClinicalA Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients With Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 With and Without Ruxolitinib in Patients With Myeloproliferative Neoplasms)Results posted
- 2026-06-01ClinicalA Phase 1/1b Open-Label, Dose Escalation, First-in- Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-leukemic Activity of the Orally Available CDC-Like Kinase (CLK) Inhibitor, BH-30236, in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML) or Higher-Risk Myelodysplastic Syndrome (HR-MDS)Primary completion
- 2026-02-01ClinicalSTOP-LEUKEMIA: Repurposing Metformin As a Leukemia-preventive Drug in CCUS and LR-MDSPrimary completion
Clinical trials
The current development programme across all trial phases.
Clinical programme
6
2
0
3
Recruiting
Recently completed
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Leading journals1
- Blood1
Leading researchers8
- Arber DA1
- Bloomfield CD1
- Borowitz MJ1
- Brunning RD1
- Harris NL1
- Hellström-Lindberg E1
- Le Beau MM1
- Porwit A1
Affiliations (unnormalised)1
- University of Chicago1
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
Conditions in which the abnormalities in the peripheral blood or bone marrow represent the early manifestations of acute leukemia, but in which the changes are not of sufficient magnitude or specificity to permit a diagnosis of acute leukemia by the usual clinical criteria.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.